Experience

Davis Polk advised the underwriters in connection with a $202.5 million public offering of common stock by Turning Point Therapeutics, Inc. Turning Point Therapeutics’ common stock is…

Davis Polk advised Texas Instruments Incorporated on its SEC-registered debt offering of $750 million aggregate principal amount of 2.250% notes due 2029. Texas Instruments is a global…

Davis Polk advised the joint book-running managers and the lead manager in connection with a $258.8 million public offering of common stock by Portola Pharmaceuticals, Inc. The common stock…

Davis Polk advised CrowdStrike Holdings, Inc. on its SEC-registered initial public offering of 20,700,000 shares of Class A common stock for an aggregate price to the public of…

Davis Polk advised the underwriters in connection with the $8.1 billion initial public offering of 180,000,000 shares of common stock of Uber Technologies, Inc. Uber’s common stock is…

Davis Polk advised Equinix, Inc. on its SEC-registered follow-on public offering of 2,985,575 shares of common stock including 389,422 shares that the underwriters…

Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre-funded warrants offering by Aeglea BioTherapeutics, Inc. The common…

Davis Polk advised Equinix, Inc. in connection with its SEC-registered at-the-market offering of its shares of common stock for up to an aggregate amount of $750 million.Equinix, Inc…

Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public offering by Taiwan Liposome Company, Ltd. of American Depositary…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $290 million initial public offering by Elastic N.V. The IPO consisted of a…